KRAS and lung carcinoma: Strikingly, the combined therapy led to much higher long-term survival advantage (log-rank test; P=0.0005; Fig. 5c).To facilitate the translation of this novel drug pair into clinical settings, we next tested the combination in a patient-derived tumour explant (PDTX) model of lung cancer carrying an activating G12D KRAS mutation.